Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Basic) (2016 - 2025)

Ptc Therapeutics has reported EPS (Basic) over the past 14 years, most recently at -$1.82 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$1.82 for Q4 2025, down 114.12% from a year ago — trailing twelve months through Dec 2025 was $8.64 (up 282.66% YoY), and the annual figure for FY2025 was $8.58, up 281.4%.
  • EPS (Basic) for Q4 2025 was -$1.82 at Ptc Therapeutics, down from $0.2 in the prior quarter.
  • Over the last five years, EPS (Basic) for PTCT hit a ceiling of $11.09 in Q1 2025 and a floor of -$2.66 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$1.77 (2022), compared with a mean of -$0.98.
  • Peak annual rise in EPS (Basic) hit 1024.17% in 2025, while the deepest fall reached 114.12% in 2025.
  • Ptc Therapeutics' EPS (Basic) stood at -$2.02 in 2021, then dropped by 16.83% to -$2.36 in 2022, then increased by 12.71% to -$2.06 in 2023, then soared by 58.74% to -$0.85 in 2024, then plummeted by 114.12% to -$1.82 in 2025.
  • The last three reported values for EPS (Basic) were -$1.82 (Q4 2025), $0.2 (Q3 2025), and -$0.83 (Q2 2025) per Business Quant data.